Immunotherapy before and after stem cell transplant for relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether adding the drug glofitamab before and after a stem cell transplant can help people with certain types of relapsed or hard-to-treat B-cell lymphoma. The goal is to see if it improves the chance of keeping the lymphoma from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a type of B-cell lymphoma that has come back or not responded to treatment, and you are scheduled for a stem cell transplant.
- You are generally well enough to carry out daily activities (performance status 0 or 1).
- You have at least one measurable tumor on a CT scan.
- Your heart, kidney, liver, and blood counts are within acceptable ranges.
- You are not pregnant and agree to use effective contraception during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
This trial tests whether adding a drug called glofitamab before and after CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) can improve outcomes for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if this combination can help you stay in remission longer.
This study tests an extra treatment called glofitamab (given as an infusion) after your first therapy has worked well, to help keep the lymphoma from coming back. It is for people with high-risk large B-cell lymphoma, and aims to improve long-term remission.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
This trial combines a targeted antibody treatment called glofitamab with radiation therapy for people whose diffuse large B-cell lymphoma has come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
Hear when a new Diffuse Large B Cell Lymphoma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.